How big is Surmodics, Inc.?

As of Jun 18, Surmodics, Inc. has a market capitalization of 415.39 million, with net sales of 121.58 million and a net profit of -19.86 million over the latest four quarters. As of September 24, the company reported shareholder's funds of 118.90 million and total assets of 178.56 million.

Market Cap: As of Jun 18, Surmodics, Inc. has a market capitalization of 415.39 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Surmodics, Inc. reported net sales of 121.58 million and a net profit of -19.86 million.<BR><BR>Balance Sheet Snapshot: As of September 24, the company reported shareholder's funds of 118.90 million and total assets of 178.56 million.

What does Surmodics, Inc. do?

Surmodics, Inc. is a micro-cap company that develops medical device and in vitro diagnostic technologies, reporting net sales of $28 million and a net loss of $5 million as of March 2025. The company has a market cap of $415.39 million and does not currently pay dividends.

Overview:<BR>Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies in the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 28 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 415.39 Million (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.00 <BR>Return on Equity: -10.26% <BR>Price to Book: 3.77 <BR><BR>Contact Details:<BR>Address: 9924 W 74th St, EDEN PRAIRIE MN : 55344-3523 <BR>Tel: 1 952 5007000 <BR>Website: http://www.surmodics.com/

Should I buy, sell or hold Surmodics, Inc.?

Who are in the management team of Surmodics, Inc.?

As of March 2022, the management team of Surmodics, Inc. includes Non-Executive Independent Chairman Ms. Susan Knight, President and CEO Mr. Gary Maharaj, and Independent Directors Mr. Jose Bedoya, Dr. David Dantzker, Ms. Lisa Heine, and Mr. Ronald Kalich. This team combines executive leadership with independent oversight for the company's governance and strategy.

As of March 2022, the management team of Surmodics, Inc. includes the following individuals:<BR><BR>- Ms. Susan Knight, who serves as the Non-Executive Independent Chairman of the Board.<BR>- Mr. Gary Maharaj, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Jose Bedoya, who is an Independent Director.<BR>- Dr. David Dantzker, who is also an Independent Director.<BR>- Ms. Lisa Heine, who serves as an Independent Director.<BR>- Mr. Ronald Kalich, who is an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is Surmodics, Inc. overvalued or undervalued?

As of July 31, 2024, Surmodics, Inc. is considered overvalued and risky due to a high Price to Book Value of 3.81, an EV to EBITDA ratio of 91.89, negative returns on equity and capital, and poor stock performance, with a year-to-date return of -18.64% compared to the S&P 500's 12.22%.

As of 31 July 2024, Surmodics, Inc. has moved from an attractive to a risky valuation grade, indicating a significant deterioration in its financial outlook. The company appears to be overvalued, with a Price to Book Value of 3.81 and an EV to EBITDA ratio of 91.89, which suggests that investors are paying a high premium for its earnings potential despite its current losses. Additionally, the negative ROE of -10.26% and ROCE of -3.57% further highlight the challenges the company faces in generating returns for shareholders.<BR><BR>In comparison to its peers, Surmodics, Inc. has a notably high EV to Sales ratio of 3.45, while Castle Biosciences, Inc. and Silk Road Medical, Inc. have ratios of 22.3090 and -18.1243, respectively, indicating that Surmodics is not only struggling but also priced higher relative to its revenue generation capabilities. The recent stock performance has been poor, with a year-to-date return of -18.64% compared to the S&P 500's positive return of 12.22%, reinforcing the notion that the stock is currently overvalued.

Is Surmodics, Inc. technically bullish or bearish?

As of August 29, 2025, Surmodics, Inc. shows a mildly bullish trend driven by weekly MACD and Bollinger Bands, despite underperforming the S&P 500 with a year-to-date return of -18.64%.

As of 29 August 2025, the technical trend for Surmodics, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD and Bollinger Bands indicate bullish momentum, while the monthly indicators show bearish signals. The daily moving averages are mildly bullish, suggesting some positive short-term sentiment. However, the Dow Theory presents a mixed view with weekly mildly bearish and monthly mildly bullish signals. Overall, the stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands.<BR><BR>In terms of performance, Surmodics has underperformed the S&P 500 across multiple periods, with a year-to-date return of -18.64% compared to the S&P 500's 12.22%.